CCM
NAGE

Cox Capital Management’s Niagen Bioscience NAGE Stock Holding History

Cox Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-92,830
Closed -$136K – 106
2023
Q3 		$136K Buy
+92,830
New +$145K 0.1% 86

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cox Capital Management's NAGE Position: Q4 2023 in Review

Cox Capital Management sold out of Niagen Bioscience (NAGE) in Q4 2023, closing a stake of 92,830 shares — an estimated $136K sold.

Cox Capital Management first reported a position in NAGE in Q3 2023 and held it in 1 quarter. The position peaked at $136K in Q3 2023. 53 funds tracked by Wall St. Rank hold NAGE as of Q4 2023.

  • Cox Capital Management reported no remaining Niagen Bioscience position as of Q4 2023 after selling out during the quarter.
  • Cox Capital Management sold 92,830 Niagen Bioscience shares in Q4 2023, an estimated $136K.
  • Cox Capital Management first reported a position in Niagen Bioscience in Q3 2023 and held it in 1 quarter.
  • Cox Capital Management's Niagen Bioscience position peaked at $136K in Q3 2023.
  • 53 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2023.

Based on Cox Capital Management's 13F filing for Q4 2023, filed 12 Jan 2024.